A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance | |
Peng, Y.B.; Zhao, Z.L.; Liu, T.; Xie, G.J.; Jin, C.; Deng, T.G.; Sun, Y.; Li, X.; Hu, X.X.; Zhang, X.B. | |
刊名 | ChemMedChem |
2017 | |
卷号 | Vol.12 No.3页码:250-256 |
关键词 | antitumor agents chlorambucil human serum albumin mitochondria nanodrugs |
ISSN号 | 1860-7179 |
URL标识 | 查看原文 |
公开日期 | [db:dc_date_available] |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6051624 |
专题 | 湖南大学 |
作者单位 | 1.a Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Biosensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, China 2.Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China 3.Department of Infectious Diseases, Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China 4.Changsha HuoZi Biological Science and Technology / Department of Urology, Third Xiangya Hospital, Central South University, Changsha, 410013, China 5.Department of Chemistry, Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Shands Cancer Center, University of Florida Genetics Institute, United States 6.f McKnight Brain Institute, University of Florida, Gainesville, FL 32611-7200, United States |
推荐引用方式 GB/T 7714 | Peng, Y.B.,Zhao, Z.L.,Liu, T.,et al. A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance[J]. ChemMedChem,2017,Vol.12 No.3:250-256. |
APA | Peng, Y.B..,Zhao, Z.L..,Liu, T..,Xie, G.J..,Jin, C..,...&Tan, W.H..(2017).A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.ChemMedChem,Vol.12 No.3,250-256. |
MLA | Peng, Y.B.,et al."A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance".ChemMedChem Vol.12 No.3(2017):250-256. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论